Extended Report

Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone

Zhuang Cui, Janet Crane, Hui Xie, Xin Jin, Gehua Zhen, Changjun Li, Liang Xie, Long Wang, Qin Bian, Tao Qiu, Mei Wan, Min Xie, Sheng Ding, Bin Yu, Xu Cao

Abstract

Objectives

Examine whether osteoarthritis (OA) progression can be delayed by halofuginone in anterior cruciate ligament transection (ACLT) rodent models.

Methods

3-month-old male C57BL/6J (wild type; WT) mice and Lewis rats were randomised to sham-operated, ACLT-operated, treated with vehicle, or ACLT-operated, treated with halofuginone. Articular cartilage degeneration was graded using the Osteoarthritis Research Society International (OARSI)-modified Mankin criteria. Immunostaining, flow cytometry, RT-PCR and western blot analyses were conducted to detect relative protein and RNA expression. Bone micro CT (μCT) and CT-based microangiography were quantitated to detect alterations of microarchitecture and vasculature in tibial subchondral bone.

Results

Halofuginone attenuated articular cartilage degeneration and subchondral bone deterioration, resulting in substantially lower OARSI scores. Specifically, we found that proteoglycan loss and calcification of articular cartilage were significantly decreased in halofuginone-treated ACLT rodents compared with vehicle-treated ACLT controls. Halofuginone reduced collagen X (Col X), matrix metalloproteinase-13 and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5) and increased lubricin, collagen II and aggrecan. In parallel, halofuginone-attenuated uncoupled subchondral bone remodelling as defined by reduced subchondral bone tissue volume, lower trabecular pattern factor (Tb.pf ) and increased thickness of subchondral bone plate compared with vehicle-treated ACLT controls. We found that halofuginone exerted protective effects in part by suppressing Th17-induced osteoclastic bone resorption, inhibiting Smad2/3-dependent TGF-β signalling to restore coupled bone remodelling and attenuating excessive angiogenesis in subchondral bone.

Conclusions

Halofuginone attenuates OA progression by inhibition of subchondral bone TGF-β activity and aberrant angiogenesis as a potential preventive therapy for OA.

Introduction

Osteoarthritis (OA), characterised by articular cartilage degeneration, joint pain and functional impairment, affects nearly 27 million people in the USA alone.1 2 There is no effective disease-modifying treatment for OA until the end stage of disease necessitating joint replacement.3 4 Despite the identified risk factors, for example, mechanical, metabolic or genetic, the exact pathogenesis of OA is still unclear5 and remains an active area of investigation as targets for preventive and disease-modifying therapies are greatly needed.

The aetiology of OA is multifactorial and includes intrinsic and extrinsic factors that propagate a multitude of cellular responses.6 The resultant phenotype includes articular cartilage degeneration, subchondral bone sclerosis and oedema, osteochondral angiogenesis, inflammation and osteophyte formation.6–8 Changes in the subchondral bone microarchitecture have been described to precede articular cartilage damage in OA.9–13 Articular cartilage and subchondral bone form a functional unit in the joint.14 15 Articular cartilage acts as a bearing, while subchondral bone acts as a structural girder and shock absorber.16 Subchondral bone, separated by the cement line from the calcified zone of the articular cartilage, consists of the subchondral bone plate (SBP) and the subarticular spongiosa.17 The architecture of subchondral bone and plate adapt via modelling and remodelling in response to mechanical stress.8 17 Coupled bone remodelling ensures the integrity of the subchondral bone, where osteoclast and osteoblast activity are temporally and spatially regulated. Specifically, osteoclasts resorb bone and generate a bone marrow microenvironment that coordinates the migration and differentiation of cells to support angiogenesis and osteogenesis for subsequent osteoblast bone formation.18–21

Following an acute injury, such as anterior cruciate ligament tear, osteoclast bone resorption dramatically increases.22–24 The subchondral bone marrow microenvironment changes substantially and results in woven bone and angiogenesis. We have previously found that excessive activation of TGF-β1 by elevated osteoclast bone resorption uncouples bone resorption and formation, contributing to the sclerotic phenotype in the subchondral bone in OA animal models.18 23 Specifically, high levels of TGF-β result in erroneous recruitment of mesenchymal/stromal stem cells (MSCs) and formation of osteoid islets. The progression of OA could be attenuated, but not completely abrogated, by inhibiting TGF-β1 signalling.25 Vascularisation and innervation of articular cartilage have also been noted in OA, with blood vessels and nerves originating from subchondral bone and breaching the
The small molecule halofuginone (HF) is an analogue of feb Rufurine, which was isolated from the plant Dichroa febrifuga in ancient Chinese herbal medicine for the treatment of malarial fever. HF has shown therapeutic promise in clinical trials for fibrotic diseases, such as scleroderma and chronic graft-versus-host disease by inhibiting phosphorylation of Smad2/3 and TGF-β-mediated collagen type I synthesis. HF has also been reported to inhibit the differentiation of the CD4+ T helper cell subset, Th17, elucidating beneficial effects in an autoimmune arthritis mouse model. Th17 functions as an osteoclastogenic CD4+ T-cell subset that links T cell activation and bone destruction. Th17 cells produce interleukin (IL)-17, inducing the expression of receptor activator of nuclear factor κ B ligand (RANKL) to promote osteoclastogenesis. TGF-β is essential for the initiation of Th17 differentiation. HF has also been shown to induce antiangiogenic effects in preclinical studies at several essential stages of angiogenesis, largely through inhibition of matrix metalloproteinase-2 (MMP-2). As increased CD4+ T-cell subsets, high TGF-β concentrations and angiogenesis have been shown to be involved in the pathogenesis of OA, we investigated the potential effect of HF as a preventive treatment for OA. We found that HF could attenuate progression of OA by delaying articular cartilage degeneration and subchondral bone sclerosis in rodent anterior cruciate ligament transection (ACLT) models by inhibiting Th17 differentiation, TGF-β-dependent Smad2/3 phosphorylation and angiogenesis.

MATERIALS AND METHODS

Three-month-old male C57BL/6J (WT) mice and Lewis rats were purchased from Charles River. Rodents were randomised to sham-operated, ACLT-operated, treated with vehicle or ACLT-operated, treated with HF. We performed histological analysis using Safranin O-fast green and H&E staining and graded articular cartilage degeneration using the Osteoarthritis Research Society International (OARSI)-modified Mankin criteria. Immunostaining, flow cytometry, RT-PCR and western blot analyses were conducted to detect relative protein expression. We quantitated bone micro CT (μCT) and CT-based microangiography parameters to detect the alterations of microarchitecture and vasculature in tibial subchondral bone. A detailed description of the Material and methods can be found in the online supplementary text.

RESULTS

HF attenuates progression of OA in ACLT mice

To investigate the effects of HF on disease activity and progression in OA, we administered HF intraperitoneally in mice after ACLT. The optimal dose (1 mg/kg body weight (mg/kg)) was identified using multiple concentrations of HF (0.2, 0.5, 1 or 2.5 mg/kg) injected every other day for 1 month post surgery (see online supplementary figure S1). Lower concentration (0.2 or 0.5 mg/kg) had minimal effects on subchondral bone and higher concentration (2.5 mg/kg) induced proteoglycan loss in articular cartilage. Specifically, Safranin O staining demonstrated retention of proteoglycan and decreased thickness of calcified cartilage.

Figure 1 Halofuginone preserves articular cartilage after anterior cruciate ligament transection (ACLT). (A) Safranin O and fast green staining (top). Solid arrows indicate proteoglycan loss and cartilage destruction at 30 and 60 days post operation. Scale bar, 500 μm. H&E staining (bottom) where calcified cartilage (CC) and hyaline cartilage (HC) thickness are marked by double-headed arrows. Scale bars, 200 μm. (B-E) Immunostaining and quantitative analysis of lubricin (B-top, C), matrix metalloproteinase (MMP) 13 (B-middle, D) and COL X (B-bottom, E) in articular cartilage at 30 days post operation. Scale bar, 100 μm. (F) Osteoarthritis Research Society International–modified Mankin scores of articular cartilage at 0, 14, 30 and 60 days after surgery. Sham=sham-surgery. Vehicle=ACLT-surgery treated with vehicle. HF=ACLT-surgery treated with halofuginone. n=6 per group. *p<0.05 compared with sham or as denoted by bar, **<0.01 compared as denoted by bar; p<0.05 compared with the vehicle.

cartilage zone (from the tidemark line to SBP) in HF-treated ACL T mice (1 mg/kg) relative to vehicle-treated ACL T controls (figure 1A and table 1). HF normalised expression of lubricin, MMP-13 and collagen X (Col X), collagen II, aggrecan and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5) as assessed by immunostaining and RT-PCR in the HF-treated ACL T mice relative to sham controls (figure 1B–E and online supplementary figures S2 and S3). OARSI scores were improved in HF-treated ACL T mice relative to vehicle-treated ACL T mice, whereas no difference was noted in HF versus sham controls (figure 1F).

**HF sustains coupled subchondral bone remodelling**

The effect of HF on the structure of tibial subchondral bone was analysed by micro-CT. HF significantly reduced the tibial subchondral bone tissue volume (TV), lowered trabecular pattern factor (Tb.pf) and increased SBP thickness post ACLT relative to vehicle treatment (figure 2A–D). There was no statistically significant difference in TV, Tb.pf or SBP thickness between the HF-treated ACL T mice and sham controls. Consistently, the number of tartrate-resistant acid phosphatase-positive osteoclast and osteoprogenitor osterix-positive cells increased after ACLT (vehicle vs sham) (figure 2E–H). The increase in both cell populations was abrogated by HF treatment (figure 2E–H). Notably, in the vehicle-treated ACL T mice, the majority of osterix-positive cells were found in clusters in subchondral bone marrow compared with localisation predominately on the bone surface in the HF-treated ACL T mice (figure 2G,H).

We also examined the effect of local administration of HF on OA progression in ACL T rats by embedding HF containing alginate beads directly into the tibial subchondral bone. Similar to administration of TGF-β neutralising antibody (1D11) in the

---

**Table 1** Cartilage thickness changes in different group and time-points (10× magnified images; mean±SD; unit: mm)

<table>
<thead>
<tr>
<th>Time (days)</th>
<th>HC Sham</th>
<th>Vehicle</th>
<th>Halofuginone</th>
<th>CC Sham</th>
<th>Vehicle</th>
<th>Halofuginone</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>0.83±0.028</td>
<td>0.79±0.046</td>
<td>0.81±0.041</td>
<td>0.32±0.032</td>
<td>0.3±0.028</td>
<td>0.28±0.037</td>
</tr>
<tr>
<td>30</td>
<td>0.81±0.028</td>
<td>0.77±0.053</td>
<td>0.81±0.023</td>
<td>0.33±0.031</td>
<td>0.34±0.052</td>
<td>0.28±0.014</td>
</tr>
<tr>
<td>60</td>
<td>0.77±0.175</td>
<td>0.45±0.18*</td>
<td>0.76±0.112†</td>
<td>0.32±0.186</td>
<td>0.65±0.19*</td>
<td>0.35±0.113†</td>
</tr>
</tbody>
</table>

† The level of significance was set at p<0.05 and indicated by † for the comparison between vehicle-treated group and sham group, or † for the comparison between halofuginone-treated group and vehicle-treated group.

CC, calcified cartilage; HC, hyaline cartilage.

---

**Figure 2** Halofuginone normalises subchondral bone after anterior cruciate ligament transection (ACLT). (A) Representative three dimensional micro-CT images of sagittal views of subchondral bone medial compartment at 30 and 60 days after sham operation or ACLT surgery. Scale bar, 500 μm. (B–D) Quantitative micro-CT analysis of tibial subchondral bone of total tissue volume (TV) (B), trabecular pattern factor (Tb.pf) (C) and subchondral bone plate thickness (D). (E and F) Tartrate-resistant acid phosphatase (TRAP) staining (E) and quantitative analysis (F) at 14 days after surgery. Scale bar, 50 μm. (G and H) Immunohistochemical staining (G) and quantification (H) of osterix-positive cells (brown) in subchondral bone 30 days after surgery. Scale bar, 100 μm. Sham=sham-surgery. Vehicle=ACLT-surgery treated with vehicle. HF=ACLT-surgery treated with halofuginone. n=6 per group. *p<0.05 compared with sham or as denoted by bar, **<0.01 compared as denoted by bar; #p<0.05 compared with the vehicle.
subchondral bone rats, articular cartilage was protected in the HF-treated rats as demonstrated by retention of proteoglycan, MMP-13 and Col X staining (see online supplementary figures S4A and S5). The subchondral bone microarchitecture was preserved with both 1D11 and HF treatments. Specifically, in the ACLT rats treated with vehicle, Tb.pf and TV were increased, while connectivity density and SBP Th. were decreased compared with sham control rats. ACLT rats treated with either HF or 1D11 did not show any statistically significant difference in these parameters relative to the sham control rats (see online supplementary figure S4A–E).

HF suppresses osteoclastogenesis by decrease of Th17 cells in the subchondral bone of mice

We examined whether HF inhibits osteoclastogenesis through modulation of Th17 cells. Immunofluorescence staining of Th17 specific markers (CD4 and IL17) revealed a significant increase of Th17 cells in the subchondral bone marrow of vehicle-treated mice as early as 2 weeks post surgery, whereas HF-treated mice had equivalent Th17 cells compared with sham controls (figure 3A,B). Consistently, a significant increase of Th17 cells (CD4+IL17+) in the bone marrow 14 days post surgery in vehicle-treated mice was also observed using flow cytometry analysis. HF-treated ACLT mice had significantly decreased Th17 cells, similar to the level of sham controls (figure 3C,D). The number of CD4+IL17+ cells in bone marrow and peripheral blood remained unchanged at different time-points (see online supplementary figure S6). Changes in bone marrow Th17 cell numbers were time-dependent, with Th17 cell numbers decreasing to baseline (0 day) in the ACLT-vehicle treated mice 2 months post surgery (see online supplementary figure S7A–C). No difference in the number of Th17 cells in peripheral blood was noted regardless of vehicle or HF-treated mice relative to sham controls (figure 3C,D).

In parallel with the increased aggregation of Th17 cells in the subchondral bone marrow of vehicle-treated mice, an increase in expression of RANKL was observed in the subchondral bone compared with sham controls (figure 3E,F). HF treatment significantly attenuated RANKL expression with no significant difference noted relative to sham controls (figure 3E,F). The results indicate HF inhibits osteoclastogenesis by decreasing Th17 cells and RANKL expression in the subchondral bone.

HF inhibits Smad2/3-dependent TGF-β signalling pathway in bone marrow MSCs

Immunofluorescence staining of nestin showed that HF significantly attenuated the increase in number of MSCs in the subchondral bone post ACLT relative to vehicle (figure 4A,B). There was no statistical difference between the number of nestin-positive cells in HF-treated ACLT mice relative to sham controls (figure 4A,B). Furthermore, nestin-positive cells were dispersed throughout the bone marrow in vehicle-treated mice compared with the closer proximity to the bone surface in the HF-treated mice (figure 4A). As high active TGF-β recruits MSCs in the subchondral bone marrow, we investigated whether HF could directly inhibit TGF-β signalling in MSCs. Western blot analysis of MSCs revealed that phosphorylation of Smad2 (pSmad2) was inhibited by HF in both a time-dependent and dose-dependent manner.

![Figure 3](http://ard.bmj.com/)

**Figure 3** Halofuginone suppresses Th17 cells after anterior cruciate ligament transection (ACLT). (A) Representative immunofluorescence double staining for CD4 (green), interleukin (IL) 17 (red) and merged images (colocalisation=yellow) 14 days after surgery. Scale bar, 50 μm. (B) Quantitative analysis of the number of CD4+IL17+ (Th17) cells per bone marrow (BM) area (mm²). (C) Flow cytometry analysis of double staining Th17 (CD4+IL17+) cells in subchondral BM 14 days post surgery. The green line represents CD4+ cells in an unstained control. (D) Flow cytometry quantitative analysis of the percentage of Th17 cell in subchondral BM and peripheral blood plasma 14 days after surgery. (E and F) Immunofluorescence staining (E) and quantification (F) for receptor activator of nuclear factor κ B ligand (RANKL) in subchondral bone 14 days post surgery. Sham=sham-surgery. Vehicle=ACLT-surgery treated with vehicle. HF=ACLT-surgery treated with halofuginone. n=6 per group. *p<0.05, compared with the sham; **p<0.05 compared with the vehicle.
dependent manner (figure 4C). Immunohistochemistry staining of pSmad2/3 further validated HF inhibition of TGF-β signal-ling in subchondral bone cells. Specifically, pSmad2/3-positive cells in the subchondral bone of vehicle-treated ACL T mice were significantly increased and attenuated with HF to levels comparable with sham mice (figure 4D,E).

**HF abrogates aberrant blood vessel formation in subchondral bone**

Finally, we examined the potential effects of HF on subchondral bone angiogenesis. Using CT-based angiography in microphil perfusion, we found the number and volume of blood vessels were significantly increased in the subchondral bone of vehicle-treated ACLT mice. HF inhibited the increase of vessel number and volume in subchondral bone relative to vehicle treatment, retaining vessel number and volume similar to sham controls (figure 5A–C). We further analysed the type of vessels inhibited by HF by performing double immunofluorescence staining for CD31 and endomucin, recently described as H-type vessels.29 CD31hiEmcnhi blood vessels were significantly increased in the subchondral bone of vehicle-treated ACLT mice. HF restored CD31hiEmcnhi blood vessels similar to sham controls (figure 5D,F). Changes in H-type vessels correlated with a similar pattern in endothelial cell proliferation as evaluated by immunostaining and quantification of the number of endomucin-positive cells that costained positive for Ki67 (figure 5E,G). Additionally, MMP-2 levels were statistically increased in vehicle-treated ACLT mice, whereas the HF-treated ACLT mice had similar MMP-2 levels compared with sham controls (figure 5H and online supplementary figure S8).

**DISCUSSION**

We have shown that HF preserves the subchondral bone microarchitecture to prevent articular cartilage degeneration by inhibition of Th17-induced osteoclastogenesis, excessive TGF-β activity and H-type vessel formation in recruitment of MSCs for aberrant bone formation. Particularly, the protection of articular cartilage by local administration of HF in the subchondral bone post ACLT in rats further suggests that maintaining the microstructural integrity of subchondral bone provides an essential physiological environment for articular cartilage. Subchondral bone undergoes remodelling in response to changes in the mechanical loading environment, such as after ACLT.8 Biochemical and biomechanical interplay between subchondral bone and articular cartilage mediates effects on articular cartilage.14

CD4+ T cell subsets are infiltrated and involved in the pathogenesis of OA,43 44 including Th17 cells.36 37 Th17 cells produce IL-17, which, in bone, induces the expression of RANKL from osteoclastogenesis-supporting mesenchymal cells to promote osteoclastogenesis.38 39 Therefore, Th17 can be regarded as an osteoclastogenic helper cell, linking T cell activation with bone destruction.39 We observed, during OA development, a significant increase of Th17 cells in the subchondral bone marrow of vehicle-treated mice as early as 2 weeks post surgery by immunofluorescence staining and flow cytometry,
with no significant changes in peripheral blood. We found the increase of Th17 cells in bone marrow was time-dependent, with Th17 cells numbers decreasing by 1 month and returning almost to baseline (0 day) by 2 months post surgery. We observed significantly increased expression of RANKL in the bone marrow in a similar time distribution. These results support that Th17 cells are involved in the onset of OA by promoting osteoclast bone resorption. The increase of Th17 cells (CD4+IL17+) and RANKL expression in bone marrow was inhibited by HF, indicating that HF inhibited osteoclastogenesis. HF is known to inhibit Th17 differentiation via inhibition of TGF-β signalling and activating the amino acid response pathway.44 TGF-β can directly and indirectly initiate Th17 differentiation.40 41 In intestinal cells, TGF-β has been shown to increase expression of Runx1, which is necessary for Th17 differentiation.46 TGF-β can also block the signalling pathways that promote Th1 and Th2 differentiation.47 48 thereby defaulting CD4+ T cell subsets to differentiate into the Th17 subtype. HF can also inhibit Th17 differentiation via activating the amino acid response pathway by suppressing prolyl-transfer RNA synthetase (ProRS) to induce uncharged tRNA accumulation within cells.49 HF directly binds onto two different binding sites of ProRS via an ATP-dependent mechanism.50

Abnormal TGF-β signalling-induced uncoupled subchondral bone remodelling precedes articular cartilage degeneration in ACLT OA mice.52 HF likely maintains coupled bone remodelling through modulation of TGF-β activity. During coupled bone remodelling, TGF-β is released and activated during osteoclast bone resorption.23 31 Smad2/3-dependent TGF-β signalling pathway induces migration of MSCs from their perivascular niche to the bone surface for osteoblast differentiation.24 However, during OA development, excessive release and activation of TGF-β will interrupt coupled bone remodelling, recruiting MSCs to form aberrant osteoid islets in bone marrow as opposed to bone resorption pits for coupled bone resorption. We found in vehicle-treated ACLT mice that the number of nestin-positive MSCs increased and clustered in bone marrow, indicating uncoupled bone remodelling. HF reduced MSCs numbers and relocated osterix-positive osteoprogenitors from the bone marrow to bone surface, re-establishing coupled bone remodelling. We speculate a combination of two mechanisms elicit this effect. The reduction in osteoclast bone resorption by HF likely reduces TGF-β release from bone matrix. Additionally, both in vitro and in vivo evidences revealed that HF directly inhibits phosphorylation of Smad2 (pSmad2) in MSCs in both a time-dependent and dose-dependent manner, and likely prevents excessive MSC migration. These results, in combination with our previous findings, suggest that HF inhibits the formation of osteoid islets by suppressing TGF-β signalling.26

Abnormal vascular congestion in subchondral bone is a known pathological feature of OA.52 OA is thought to progress by osteochondral angiogenesis where blood vessels breach the tidemark at the osteochondral junction.33 34 HF inhibits angiogenesis through indirectly inhibiting MMP-2-dependent tubular network formation.52 MMP-2 can degrade structural extracellular matrix by cleaving type IV collagen,53 54 the protein backbone of the endothelial basement membrane, then promote

![Figure 5](https://example.com/figure5.png)

**Figure 5** Halofuginone attenuates aberrant angiogenesis in subchondral bone of anterior cruciate ligament transection (ACLT) mice. (A–C) Three dimensional CT-based microangiography of medial tibial subchondral bone (A) 30 days post surgery, with a quantification of vessel volume relative to tissue volume (VV/TV) (B) and vessel number (VN) (C). Scale bar, 500 μm. (D and F) Representative immunofluorescence double staining (D) and quantification (F) of CD31 (green) and endomucin (red) positive cells 1 month after surgery. Scale bar, 50 μm. (E and G) Immunofluorescence double staining (E) and quantification (G) of Ki67 (green) and endomucin (red) positive cells 1 month after surgery. Scale bar, 50 μm. (H) Quantification of MMP-2 positive cells in subchondral bone marrow (BM) 1 month post surgery. Sham=sham-surgery treated with vehicle. Vehicle=ACLT-surgery treated with vehicle. HF=ACLT-surgery treated with halofuginone. n=6 per group. *p<0.05 compared with sham and #p<0.05 compared with vehicle.
angiogenesis.\textsuperscript{57} The significantly increased expression of MMP-2 in vehicle-treated ACLIT mice was normalised with HF. TGF-β signalling in endothelial progenitor cells can also induce angiogenesis.\textsuperscript{58} We have previously shown that TGF-β inhibition can reduce angiogenesis in subchondral bone in ACLIT OA mice.\textsuperscript{26} The normalisation of vessel volume and numbers in ACLIT mice treated with HF was thus likely secondary to indirect suppression of MMP-2, direct inhibition of TGF-β signalling or other additional unexplored mechanisms. We further investigated whether the increase in vascularity is from H-type vessels. H-type vessels, defined by high containing for CD31 and endomucin (CD31\textsuperscript{hi}Emcn\textsuperscript{hi}), is a specific subtype of vessels that couples angiogenesis with osteogenesis.\textsuperscript{20, 29} Building on our prior findings that demonstrated the formation of an ‘osteoid islet’ during OA development,\textsuperscript{26} we found the increase in vascularity within the ‘osteoid islet’ was H-type vessels. H-type vessels increased after ACLIT, but were equivalent to sham-operated controls when ACLIT-mice were treated with HF. These results suggest that HF can attenuate OA progression by prevention of pathological angiogenesis.

The immune system has also been implicated in the pathogenesis of OA. HF has been shown to decrease nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) and p38 mitogen-activated protein kinases (MAPK) in activated T cells in vitro with anticipated downstream signalling effects, such as lower interferon (INF)-γ and tumour necrosis factor α concentrations.\textsuperscript{59} This may be an additional mechanism, particularly as HF has shown beneficial effects in an autoimmune arthritis mouse model.\textsuperscript{35} More detailed studies are required to comprehensively understand the effects of HF on the immune system, particularly adaptive immunity.

Febrifugine has been used in Chinese herbal medicine for more than 2000 years.\textsuperscript{30, 31, 60} The small molecule HF, a derivative of febrifugine, has been granted orphan drug status for scleroderma and Duchenne muscular dystrophy (DMD). HF has shown therapeutic promise in clinic trials for scleroderma and chronic graft-versus-host disease.\textsuperscript{32, 33} and is currently being investigated in effectiveness of reversing muscle fibrosis in DMD.\textsuperscript{61} Our findings broaden the potential clinical application of HF. We found that HF-attenuated OA progression by targeting three subchondral bone pathological features in the early OA in rodent ACLIT models. HF prevented subchondral bone changes, including reduced T	extsubscript{h}17-induced osteoclast bone resorption, reduced aberrant bone formation through inhibition of TGF-β signalling and aberrant H-type blood vessel formation. Most importantly, articular cartilage degeneration was attenuated, suggesting that targeting of subchondral bone changes in early OA may be an effective preventive strategy.

Correction notice This article has been corrected since it was published Online First. The author Min Xie has been added.

Contributors All authors meet the International Committee of Medical Journal Editors recommendations. All authors have critically reviewed the manuscript.

Funding This work was supported in part by the NIH grants AR 06394 and DK 057501 (to XC).

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Basic and translational research


Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone

Zhuang Cui, Janet Crane, Hui Xie, Xin Jin, Gehua Zhen, Changjun Li, Liang Xie, Long Wang, Qin Bian, Tao Qiu, Mei Wan, Min Xie, Sheng Ding, Bin Yu and Xu Cao

Ann Rheum Dis published online October 15, 2015

Updated information and services can be found at:
http://ard.bmj.com/content/early/2015/11/07/annrheumdis-2015-207923

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2015/10/15/annrheumdis-2015-207923.DC1

References
This article cites 61 articles, 14 of which you can access for free at:
http://ard.bmj.com/content/early/2015/11/07/annrheumdis-2015-207923#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (595)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Osteoarthritis (931)
Calcium and bone (725)
Immunology (including allergy) (5144)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/